We Claim:

1. A method for detecting an analyte in a sample, comprising:

providing a suspension of colloidal particles, wherein said particles are associated with a ligand that binds to said analyte, and wherein said colloidal particles are near a dynamical phase transition state;

contacting said suspension with said sample; and

determining whether said colloidal particles transition from a first phase to a second phase, wherein such transition is indicative of said analyte being present in said sample.

- 2. The method of Claim 1, wherein said colloidal particles comprise a lipid layer.
- 3. The method of Claim 2, wherein said lipid layer comprises a lipid bilayer.
- 4. The method of Claim 3, wherein said lipid bilayer comprises a natural cell membrane.
- 5. The method of Claim 3, wherein said lipid bilayer comprises an artificial cell membrane.
- 6. The method of Claim 1, wherein said colloidal particles are covalently linked to said ligand.
- 7. The method of Claim 1, wherein said ligand is non-covalently linked to said colloidal particles.
- 8. The method of Claim 1, wherein said ligand is interspersed within a lipid layer on said colloidal particles.
- 9. The method of Claim 1, wherein said colloidal particles have a net negative charge or a net neutral charge.
- 10. The method of Claim 1, wherein said analyte is selected from the group consisting of: a protein, a nucleic acid, an antibody, an antigen, a receptor, a virus, and a bacteria.
- 11. The method of Claim 1, wherein determining whether said colloidal particles transition from a first phase to a second phase comprises measuring the distances between centers of said colloidal particles in said suspension.
- 12. The method of Claim 1, wherein said colloidal particles are between $1\mu m$ and $10\mu m$
- 13. The method of Claim 1, wherein said first phase is a condensed phase and said second phase is a dispersed phase.
- 14. The method of Claim 1, wherein said first phase is a dispersed phase and said second phase is a condensed phase.
- 15. The method of Claim 1, wherein said suspension of colloidal particles comprises a first population of colloidal particles and a second population of colloidal particles.

- 16. The method of Claim 15, wherein said first population comprises colloidal particles that are larger than the colloidal particles in said second population.
- 17. The method of Claim 15, wherein said first population comprises colloidal particles that are labeled differently than the colloidal particles in said second population.
 - 18. An assay system for detecting the binding of an analyte to a ligand, comprising: a suspension of colloidal particles, wherein said colloidal particles are near a dynamical phase transition state;
 - a ligand associated with said particles and specific for said analyte; and
 - a device configured to determine if said colloidal particles transition from a first phase to a second phase when contacted by said analyte, wherein such transition is indicative of said analyte being bound to said ligand.
- 19. The assay system of Claim 18, wherein said suspension of colloidal particles comprises a first population of colloidal particles and a second population of colloidal particles.
- 20. The assay system of Claim 19, wherein said first population comprises colloidal particles that are larger than the colloidal particles in said second population.
- 21. The assay system of Claim 19, wherein said first population comprises colloidal particles that are labeled differently than the colloidal particles in said second population.
- 22. The assay system of Claim 18, wherein said colloidal particles comprise a lipid layer.
- 23. The assay system of Claim 22, wherein said lipid layer comprises a natural cell membrane.
- 24. The assay system of Claim 18, wherein said colloidal particles are covalently linked to said ligand.
- 25. The assay system of Claim 18, wherein said ligand is non-covalently linked to said colloidal particles.
- 26. The assay system of Claim 18, wherein said first phase is a condensed phase and said second phase is a dispersed phase.
- 27. The assay system of Claim 18, wherein said first phase is a dispersed phase and said second phase is a condensed phase.
 - 28. An assay system for detecting the binding of an analyte to a ligand, comprising:
 a suspension of colloidal particles, wherein said particles are coated with a lipid layer, and wherein said particles are near a dynamical phase transition state;
 - a ligand associated with said lipid layer, wherein said ligand is specific for said analyte; and

means for detecting if said colloidal particles transition from a first phase to a second phase when contacted by said analyte, wherein such transition is indicative of said analyte being bound to said ligand.

- 29. The assay system of Claim 28, wherein said means for detecting comprises a microscope.
- 30. The assay system of Claim 28, wherein said means for detecting comprises a florescence detector.
- 31. The assay system of Claim 28, wherein said lipid layer comprises a natural cell membrane.
- 32. The assay system of Claim 28, wherein said ligand is non-covalently linked to said lipid layer.